Bucillamine in Treatment of Patients With COVID-19
- Registration Number
- NCT04504734
- Lead Sponsor
- Revive Therapeutics, Ltd.
- Brief Summary
This is a Phase 3, multi-center, randomized, double blind, placebo controlled, clinical study of bucillamine (2 dosage levels) in patients with mild-moderate COVID-19. Patients will be randomized 1:1:1 to receive bucillamine 100 mg 3 times a day (TID), bucillamine 200 mg TID or placebo TID for up to 14 days. After the first interim analysis when a single dose is selected, patients will then be randomized 1:1 to the selected bucillamine dose or placebo. This dose has now been chosen as 600 mg. The study will be overseen by an independent Data and Safety Monitoring Board (DSMB). Up to 50 centers in the United States will conduct this study. Up to 1000 patients will be enrolled in this study. Patients will participate in the study approximately 45 days.
- Detailed Description
This is a Phase 3, multi-center, randomized, double blind, placebo controlled, clinical study of bucillamine (2 dosage levels) in patients with mild-moderate COVID-19. Patients will be randomized 1:1:1 to receive bucillamine 100 mg 3 times a day (TID), bucillamine 200 mg TID or placebo TID for up to 14 days. After the first interim analysis when a single dose is selected, patients will then be randomized 1:1 to the selected bucillamine dose or placebo. This dose has now been chosen as 600 mg. The study will be overseen by an independent Data and Safety Monitoring Board (DSMB). Up to 50 centers in the United States will conduct this study.
Patients qualifying for study enrollment will initiate therapy as outpatients, under home quarantine. Patients will receive continued standard care of therapy (per study site written policies or guidelines) together with bucillamine and/ or matching placebo for up to 14 days. Dosing should continue until the treatment course is completed or as medically indicated (e.g., deterioration of clinical status and alternative therapy required). If the patient requires hospitalization during the study period, treatment will be discontinued.
Following completion of the treatment course, follow up assessments will be performed by a study nurse 14, 28, 42, and 60 days following the end of treatment.
Up to 1000 patients will be enrolled in this study. Patients will participate in the study approximately 45 days.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 713
- Is within 72 hours from onset of symptoms consistent with COVID 19 at time of study enrollment
- Has at least 2 of the following: fever (oral temperature ≥38°C), cough, shortness of breath, chest x ray changes consistent with COVID-19 at time of screening
- Has peripheral capillary oxygen saturation (SpO2) ≥94 by pulse oximetry at time of screening
- Has either a laboratory-confirmed SARS-CoV-2 infection as determined by FDA-approved rapid diagnostic (e.g., PCR) assay
- Has a score of ≤ 2 on the 8-category NIAID ordinal scale at time of screening
- Agrees to the collection of blood and urine samples, nasopharyngeal (NP) swabs, and non-invasive oxygen monitoring (via pulse oximeter) per protocol
- Patient (or their legally authorized representative) is willing and able to provide written informed consent prior to performing study procedures
- Understands and agrees to comply with planned study procedures
- Women of childbearing potential must agree to either abstinence or use at least 1 primary form of contraception not including hormonal contraception from the time of screening through Day 29 following randomization. All subjects of childbearing potential, including males with partners of childbearing potential, must use highly effective methods of birth control defined as those, alone or in combination, that result in a low failure rate (i.e., less than 1 percent per year) when used consistently and correctly. Abstinence is NOT an acceptable method of contraception UNLESS it is the subject's normal practice.
- Prior history of, or considered to be at risk for, agranulocytosis, nephropathy, liver disease, or interstitial pneumonia
- Serious hepatic disorder (Child-Pugh scores B or C) or alanine transaminase (ALT) or aspartate transaminase (AST) > 5 times the upper limit of normal (ULN) at screening
- Chronic kidney disease (CKD) National Kidney Foundation (NKF) stages 3B - 5 chronic renal dysfunction (estimated glomerular filtration rate [eGFR] <45 mL/min/1.73m2 according to Cockcroft Gault formula)
- Proteinuria ≥ 1+ or ≥ 30 mg on dipstick urinalysis that is confirmed on repeat assessment within 24 hours
- Serum BUN ≥ 2 × ULN or Cr ≥ 2 × ULN
- Leukopenia with absolute granulocyte count < 1500/µL
- History of positive Human Immunodeficiency virus (HIV) test or organ transplant
- Receipt of cancer chemotherapy or immunomodulatory drugs including (but not limited to) biologics such as anti-CD20, anti-TNF, anti-IL6; alkylating agents (e.g., cyclophosphamide); antimetabolites (e.g., azathioprine); or chronic corticosteroid use equivalent to prednisone >10 gm/day, during preceding 2 months
- Confirmed positive for influenza at screening
- Confirmed positive for respiratory syncytial virus (RSV) at screening
- Pregnant or breastfeeding
- Current use of, or known allergy to bucillamine or penicillamine (e.g., for Wilson's disease, rheumatoid arthritis)
- Current participation in any other clinical trial of an experimental treatment
- Receipt of any experimental treatment for COVID-19 (herbal/homeopathic, off-label, compassionate use, or trial related) within the 30 days prior to screening
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Bucillamine high dose Bucillamine Bucillamine 200 mg 3 times a day (TID) Placebo Placebo Placebo, 3 times a day (TID) Bucillamine low dose Bucillamine Bucillamine 100 mg 3 times a day (TID)
- Primary Outcome Measures
Name Time Method Efficacy: Frequency of hospitalization or death From time of first dose through Day 28 following randomization Proportion of patients meeting a composite endpoint of hospitalization or death
- Secondary Outcome Measures
Name Time Method Safety: Changes in adverse events from baseline to end of study From time of first dose through Day 28 following randomization Number of adverse events
Trial Locations
- Locations (43)
Sweet Hope Research Specialty Inc
🇺🇸Hialeah, Florida, United States
Columbus Clinical Services
🇺🇸Miami, Florida, United States
Entrust Clinical Research
🇺🇸Kendall, Florida, United States
Encore Medical Research
🇺🇸Hollywood, Florida, United States
Revive Research Institute Inc.
🇺🇸Farmington Hills, Michigan, United States
Cullman Clinical Trials
🇺🇸Cullman, Alabama, United States
HealthStar Research LLC
🇺🇸Hot Springs, Arkansas, United States
ASCADA Research
🇺🇸Huntington Beach, California, United States
Superior Clinical Research
🇺🇸Yanceyville, North Carolina, United States
Dayton Clinical Research
🇺🇸Dayton, Ohio, United States
Avant Research Associates, LLC
🇺🇸Huntsville, Alabama, United States
Clinical Site Partners LLC
🇺🇸Winter Park, Florida, United States
OnSite Clinical Solutions
🇺🇸Charlotte, North Carolina, United States
Amavita Clinical Research
🇺🇸North Miami Beach, Florida, United States
Encore Medical Research of Weston LLC
🇺🇸Weston, Florida, United States
American Clinical Trials LLC
🇺🇸Acworth, Georgia, United States
Quad Clinical Research LLC
🇺🇸Chicago, Illinois, United States
Koch Family Medicine
🇺🇸Morton, Illinois, United States
Monroe Biomedical Research
🇺🇸Monroe, North Carolina, United States
OnSite Clinical Solutions, LLC
🇺🇸Charlotte, North Carolina, United States
Revival Research Institute LLC
🇺🇸Sterling, Michigan, United States
SRI International
🇺🇸Plymouth, Michigan, United States
Family Practice Center
🇺🇸McAllen, Texas, United States
FMC Science
🇺🇸Lampasas, Texas, United States
Samuel Ross MD Inc.
🇺🇸Los Angeles, California, United States
C & R Research Services USA
🇺🇸Houston, Texas, United States
Great Lakes Research Institute
🇺🇸Southfield, Michigan, United States
Physicians Quality Care
🇺🇸Jackson, Tennessee, United States
Novaceut Clinical Research
🇺🇸Clarksville, Tennessee, United States
Inquest Clinical Research
🇺🇸Baytown, Texas, United States
Encore Imaging and Medical Research
🇺🇸Houston, Texas, United States
R & H Clinical Research Inc.
🇺🇸Stafford, Texas, United States
Renovatio Clinical
🇺🇸The Woodlands, Texas, United States
Amicis Research Center
🇺🇸Northridge, California, United States
Dr. Orvil Martínez-Rivera
🇵🇷San Juan, Puerto Rico
West Valley Research Clinic
🇺🇸Phoenix, Arizona, United States
Optimus Medical Group
🇺🇸San Francisco, California, United States
Verus Clinical Research
🇺🇸Miami, Florida, United States
Nuren Medical & Research Center
🇺🇸Miami, Florida, United States
Advance Medical Research Services Corp
🇺🇸Miami, Florida, United States
Machuca Family Medicine
🇺🇸Las Vegas, Nevada, United States
Pharmacorp Clinical Trials Inc.
🇺🇸Charleston, South Carolina, United States
Prime Global Research
🇺🇸Bronx, New York, United States